The mutational landscape of meningioma has expanded following the use of the new
genetic sequencing approaches. Novel mutations have been characterized and reveal their …

Meningiomas are common intracranial tumors with a female predominance. Their etiology is
still poorly documented. The role of sexual hormones has long been evoked, and data have …

Objective To assess the risk of meningioma associated with use of high dose cyproterone
acetate, a progestogen indicated for clinical hyperandrogenism. Design Observational …

Background and purpose A dose‐dependent association between the use of cyproterone
acetate (CPA) and intracranial meningioma has been identified but data for other potent …

Objective The great heterogeneity of meningiomas is challenging and we need to
distinguish relevant subgroups. Spheno-orbital osteomeningiomas (SOOM) constitute a …

Purpose To report the results of systematic meningioma screening program implemented by
French authorities in patients exposed to progestin therapies (cyproterone (CPA) …

Meningiomas are the most commonly diagnosed benign intracranial adult tumors. Subsets
of meningiomas that present with extensive invasion into surrounding brain areas have high …

Objective The aim of this study was to describe progestin-associated meningiomas'
characteristics, outcome and management. Material and methods We included 53 patients …

OBJECTIVE To investigate the relationship between growth kinetics of intracranial
meningiomas and usage of the progestin cyproterone acetate (PCA). METHODS This study …

Background: Gender-affirming hormone therapy is critical to the management of transgender
persons. Cyproterone acetate (CPA) is a synthetic, progesterone-like compound commonly …